Organicell Regenerative Medicine, Inc.: management transactions · United States · SEC (Form 4)

About Organicell Regenerative Medicine, Inc.

Organicell Regenerative Medicine, Inc. is a U.S.-based biotechnology / regenerative medicine company that has been associated with the U.S. micro-cap market and, in recent SEC disclosures, with a transition to the name Zeo ScientifiX; from an investor’s standpoint, it remains a speculative healthcare name rather than a scaled commercial pharmaceutical platform. The company was incorporated in Nevada on August 9, 2011, originally under the name Bespoke Tricycles Inc., later renamed Biotech Products Services and Research, Inc., and then Organicell Regenerative Medicine, Inc. in 2018. Its principal offices and operating footprint are in Florida, with management and business addresses in Miami/Davie and an extracellular-vesicle processing lab in Davie, Florida, confirming that the business is firmly rooted in the United States.([sec.gov](https://www.sec.gov/Archives/edgar/data/1557376/000182912624001677/zeoscientifixinc_10q.htm)) At its core, the company focuses on the development, manufacturing, and commercialization of biological therapeutics for degenerative diseases and regenerative medicine. Management describes the company’s proprietary products as perinatal-source biologics designed to preserve naturally occurring extracellular vesicles, hyaluronic acid, and proteins, alongside an autologous, non-manipulated biologic derived from a patient’s peripheral blood. The most visible branded assets include Zofin™ (also referred to as Organicell™ Flow), identified in SEC filings as the flagship product, and Patient Pure X™ (PPX™), a newer autologous service platform that has generated only minimal revenue to date. The company also sells products under the ZEO ScientifiX brand, with several product references visible on its own ordering site.([sec.gov](https://www.sec.gov/Archives/edgar/data/1557376/000182912624001677/zeoscientifixinc_10q.htm)) From a competitive perspective, Organicell operates in a crowded regenerative medicine landscape populated by larger, better-capitalized biopharma, biologics, and medical-device companies. Its differentiation appears to rest on proprietary extracellular-vesicle-oriented biology, a physician-and-clinic distribution model, and niche positioning in regenerative and anti-aging related applications. SEC filings indicate that the company’s sales channels rely materially on distributors and medical practices, with no exclusive customer dependence disclosed, suggesting a relatively concentrated and still-developing commercial footprint.([sec.gov](https://www.sec.gov/Archives/edgar/data/1557376/000182912624001677/zeoscientifixinc_10q.htm)) Recent corporate milestones have been significant. The company changed its name from Organicell Regenerative Medicine, Inc. to Zeo ScientifiX, Inc., effective February 20, 2024, and FINRA processed the related symbol change in March 2024. It also completed a 1-for-200 reverse stock split in late 2023. More recent SEC disclosures show continued regulatory engagement, including IND and emergency IND approvals for certain protocols, while also emphasizing financing constraints and going-concern risk. For investors, the key takeaway is that this remains a U.S.-listed healthcare microcap with a differentiated scientific narrative, but one that still faces execution, regulatory, commercialization, and dilution risks before it can translate R&D into durable revenue.([sec.gov](https://www.sec.gov/Archives/edgar/data/1557376/000182912624001677/zeoscientifixinc_10q.htm))